<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3134">
  <stage>Registered</stage>
  <submitdate>14/03/2011</submitdate>
  <approvaldate>14/03/2011</approvaldate>
  <nctid>NCT01335009</nctid>
  <trial_identification>
    <studytitle>Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma</studytitle>
    <scientifictitle>A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MORAb-004-201MEL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MORAb-004 (monoclonal antibody)

Experimental: MORAb-004, 2 mg/kg - Biologic (monoclonal antibody)

Experimental: MORAb-004, 4 mg/kg - Biologic (monoclonal antibody)


Other interventions: MORAb-004 (monoclonal antibody)
Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) rate based on RECIST - Evaluate the rate of PFS at 24 weeks for two dose levels of MORAb-004 based on RECIST (radiographic measure of tumors)</outcome>
      <timepoint>after 80 subjects complete 24 weeks of treatment</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed diagnosis of metastatic melanoma

          -  At least one prior line of systemic treatment with confirmed progression of disease

          -  Measurable disease, as defined by RECIST, assessed within 4 wks prior to study entry

          -  At least 3 week interval between first infusion of test article and most recent prior
             systemic anticancer therapy

          -  ECOG Performance Status of 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of other active malignancy requiring treatment within the last 5 years (other
             than basal cell or squamous cell carcinoma of the skin), or active brain metastasis

          -  Clinically significant heart disease (Congestive heart failure of NYHA Class 3 or 4,
             angina not well controlled by medication, or myocardial infarction within 6 mos.), or
             ECGs demonstrating clinically significant arrhythmias

          -  Brain metastasis

          -  Known allergic reaction to a prior monoclonal antibody therapy

          -  Previous treatment with MORAb-004</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>16/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>Sydney Cancer Center - Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Newcastle Melanoma Unit, Calvery Mater Newcastle - Waratah</hospital>
    <hospital>The Crown Princess Mary Cancer Centre, Westmead Hospital - Westmead</hospital>
    <hospital>Princess Alexandra Hospital - Wooloongabba</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Wooloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Morphotek</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a global, Phase 2, open label, dose selection, proof-of-concept study to assess
      progression free survival in subjects with metastatic melanoma.

      80+ subjects at 29 sites in the U.S., U.K., Germany and Australia will be randomized into one
      of two dose groups: 2 mg/kg, 4 mg/kg. Weekly treatment will continue until disease
      progression.

      Subjects must have measurable disease by CT Scan or MRI and must have completed at least one
      prior round of chemotherapy.

      Subjects will be assessed for Efficacy, PK/PD, Overall survival, and Safety (Adverse
      Events/Adverse Events of Interest, Electrocardiograms (ECG's), clinical labs, physical
      exams/vital signs, tolerability).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01335009</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>